Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) has provided an update.
Sawai Group Holdings Co., Ltd. has announced a financial provision for a loss on litigation related to a patent infringement settlement concerning its Teriparatide Subcutaneous Injection. The company will recognize a 4 billion yen expense in its financial results for the second quarter of the fiscal year ending March 31, 2026. Despite this expense, the company has maintained its previously announced dividend amounts, indicating a stable financial outlook.
The most recent analyst rating on (JP:4887) stock is a Hold with a Yen1980.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of generic drugs. The company is known for its commitment to providing affordable and high-quality medication, primarily serving the Japanese market.
Average Trading Volume: 385,903
Technical Sentiment Signal: Hold
Current Market Cap: Yen185.6B
See more insights into 4887 stock on TipRanks’ Stock Analysis page.